Identification of a Novel *De Novo* Variant in the *PAX3* Gene in Waardenburg Syndrome by Diagnostic Exome Sequencing: The First Molecular Diagnosis in Korea

Mi-Ae Jang, M.D.1*, Taeheon Lee, Ph.D.2, Junnam Lee, M.S.2, Eun-Hae Cho, M.D.2, and Chang-Seok Ki, M.D.1
Department of Laboratory Medicine and Genetics1, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Green Cross Genome2, Yongin; Korea

Waardenburg syndrome (WS) is a clinically and genetically heterogeneous hereditary auditory pigmentary disorder characterized by congenital sensorineural hearing loss and iris discoloration. Many genes have been linked to WS, including *PAX3*, *MITF*, *SNAI2*, *EDNRB*, *EDN3*, and *SOX10*, and many additional genes have been associated with disorders with phenotypic overlap with WS. To screen all possible genes associated with WS and congenital deafness simultaneously, we performed diagnostic exome sequencing (DES) in a male patient with clinical features consistent with WS. Using DES, we identified a novel missense variant (c.220C>G; p.Arg74Gly) in exon 2 of the *PAX3* gene in the patient. Further analysis by Sanger sequencing of the patient and his parents revealed a de novo occurrence of the variant. Our findings show that DES can be a useful tool for the identification of pathogenic gene variants in WS patients and for differentiation between WS and similar disorders. To the best of our knowledge, this is the first report of genetically confirmed WS in Korea.

**Key Words:** Exome, PAX3, Waardenburg syndrome

Waardenburg syndrome (WS) is a rare autosomal dominant disorder characterized by congenital sensorineural hearing loss and pigmentary disturbances of the iris, hair, and skin, with or without dystopia canthorum [1]. Its prevalence is estimated to be 1/42,000, and it is responsible for 1-3% of all congenital deafness cases [2].

Four subtypes of WS have been described thus far. WS type I (WS1; MIM 193500) includes dystopia canthorum (an outward displacement of the inner canthi), and this feature distinguishes WS1 from WS type II (WS2; MIM numbers 193510, 600193, 606662, 608890, and 611584 for 2A to 2E) [3]. WS type III (WS3; MIM 148820) is similar to WS1 but includes musculoskeletal anomalies of the upper limbs. WS type IV (WS4; MIM numbers 277580, 613265, and 613266 for 4A to 4C) is similar to type I but has features of Hirschsprung disease [4]. Despite many efforts to clinically differentiate between the subtypes of...
WS by diagnostic criteria [5], the rarity and highly varied expression has limited the ability to make an accurate diagnosis in individual patients. In addition, hearing loss and early graying are relatively common in the general population and are not specific to WS [6]. Thus, the accuracy of WS diagnosis needs to be improved by the use of additional diagnostic procedures.

In addition to the variable phenotypic expressivity of WS, the genetic heterogeneity also creates significant challenges for both clinical diagnosis and genetic counseling. Many causative genes have been identified for WS and are the basis of disease classification as follows: WS1 (causative gene: PAX3), WS2 (MITF, SNAI2, and SOX10), WS3 (PAX3), and WS4 (EDNRB, EDN3, and SOX10) [1]. Furthermore, many genes are associated with deafness and hearing loss that should be differentiated, such as DIAPH1, KCNQ4, GJB3, GJB2, GJB6, MYH14, DFNA5, WFS1, TECTA, and COCH [6].

Recently, diagnostic exome sequencing (DES) has been introduced to analyze the exons and flanking intronic regions of these genes with clinical relevance. DES is appropriate for a variety of exome sequencing indications providing lower turnaround times, lower cost, more comprehensive coverage of target regions without the complexity of whole exome analysis. Given that there are potentially many genes associated with WS and that similar clinical phenotypes may be problematic for diagnosis, we performed DES to identify a pathogenic variant in a Korean patient suspected of having WS.

A 27-yr-old man with bilateral hearing impairment presented to our hospital for genetic diagnosis. His prenatal history was unremarkable, and no pregnancy concerns were reported. He had heterochromia of the right iris, but dystopia canthorum was unexpected. As conventional gene-by-gene sequencing is too costly and time-consuming, DES, which allows simultaneous analysis of potentially many genes associated with WS and that similar clinical phenotypes may be problematic for diagnosis, we performed DES to identify a pathogenic variant in a Korean patient suspected of having WS.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

Recently, exome sequencing was introduced to analyze the exons and flanking intronic regions of these genes with clinical relevance. DES is appropriate for a variety of exome sequencing indications providing lower turnaround times, lower cost, more comprehensive coverage of target regions without the complexity of whole exome analysis. Given that there are potentially many genes associated with WS and that similar clinical phenotypes may be problematic for diagnosis, we performed DES to identify a pathogenic variant in a Korean patient suspected of having WS.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.

A mean coverage of 105.49× was achieved, and 95.21% of targeted bases were read >20 times by exome capture and sequencing. A total of 92,759 SNPs were identified, and the pathogenic variant identified by DES was confirmed by using conventional Sanger sequencing.
Patients with rare diseases often undergo a lengthy, time-consuming process for a definitive diagnosis, commonly referred to as a “diagnostic odyssey.” This is due to clinical and genetic heterogeneity of the hereditary condition, unusual presentation, and lack of specific clinical-genetic knowledge of the attending physicians [11]. The use of next-generation sequencing (NGS) technologies to examine multi-gene targeted panels might be useful for diseases with genetic heterogeneity. If NGS is performed early on, patients may escape the tedious, expensive, and emotionally wrenching “diagnostic odyssey” [12].

There are many multi-gene targeted panels for single diseases such as cancer, cardiac disease, immune disorders, and neurological disorders. The TruSight One Sequencing Panel provides the largest coverage of 4,813 clinically relevant genes available, which are selected on the basis of information in the Human Gene Mutation Database (HGMD), the Online Mendelian Inheritance in Man (OMIM), and other commercially available sequencing panels. Laboratories can analyze all of the genes on the panel or focus on a specific subset. As in the present case, this new diagnostic sequencing significantly shortens the diagnostic process, especially in conditions that have phenotypic overlap with a variety of single-gene disorders.

The PAX3 gene is located on chromosome 2q36.1 and encodes a DNA-binding transcription factor expressed in neural crest cells [13]. It plays an important role in the development and differentiation of melanocytes, which originate from the embryonic neural crest [13]. The PAX3 protein contains two highly conserved DNA binding domains, a paired domain and a homeodomain corresponding to exons 2-6 of the PAX3 gene. To date, more than 100 PAX3 pathogenic variants have been reported to be associated with WS (HGMD professional version for release 2014.2). Approximately 95% of the PAX3 pathogenic variants are located in DNA binding domains, and the highest proportion of pathogenic variants is found in exon 2 of the paired domain [1]. Matsunaga et al. [14] reported that the p.Ile59Phe pathogenic variant, which is located in the paired domain, is likely to distort the structure of the DNA-binding site of PAX3 and lead to functional impairment. The novel pathogenic variant found in this study is predicted to alter the highly conserved arginine at codon 74, which plays a role in paired domain DNA binding; therefore, it may influence DNA-binding activity and transactivation capabilities resulting in a disease phenotype. Further functional study is needed to confirm its causal mechanism.

To the best of our knowledge, this is the first molecular genetic analysis of a WS1 patient from the Korean population. We identified a novel missense pathogenic variant (c.220C>G; p.Arg47Gly) in the PAX3 gene. To date, no molecular confirmation has been performed in such cases to date.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.
REFERENCES

1. Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat 2010;31:391-406.
2. Read AP and Newton VE. Waardenburg syndrome. J Med Genet 1997;34:656-65.
3. Pardono E, van Bever Y, van den Ende J, Havrenne PC, Iughetti P, Maestrelli SR, et al. Waardenburg syndrome: clinical differentiation between types I and II. Am J Med Genet A 2003;117A:223-35.
4. Wildhardt G, Zirn B, Graul-Neumann LM, Wechtenbruch J, Suckfüll M, Buske A, et al. Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics. BMJ Open 2013;3:e001917.
5. Farrer LA, Grundfast KM, Amos J, Arnos KS, Asher JH Jr, Beighton P, et al. Waardenburg syndrome (WS) type I is caused by defects at multiple loci, one of which is near ALPP on chromosome 2: first report of the WS consortium. Am J Hum Genet 1992;50:902-13.
6. Ouyang XM, Yan D, Yuan HJ, Pu D, Du LL, Han DY, et al. The genetic bases for non-syndromic hearing loss among Chinese. J Hum Genet 2009;54:131-40.
7. Choi JH, Moon SK, Lee KH, Lew HM, Chang YH. Three Cases of Waardenburg syndrome type 2 in a Korean family. Korean J Ophthalmol 2004;18:185-9.
8. Kee SY, Lee YC, Lee SY. Type 3 Waardenburg syndrome. J Korean Ophthalmol Soc 2005;46:726-30.
9. Lee SC. A case of Waardenburg syndrome type 2 with anisocoria. J Korean Ophthalmol Soc 2010;51:1423-6.
10. Shim HC, Kim JK, Park DJ. A case of Waardenburg syndrome type 4. J Korean Ophthalmol Soc 2013;54:176-9.
11. Lohmann K and Klein C. Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics 2014;11:699-707.
12. Gomez CM and Das S. Clinical exome sequencing: the new standard in genetic diagnosis. JAMA Neurol 2014;71:1215-6.
13. Strachan T and Read AP. PAX genes. Curr Opin Genet Dev 1994;4:427-38.
14. Matsunaga T, Mutai H, Namba K, Morita N, Masuda S. Genetic analysis of PAX3 for diagnosis of Waardenburg syndrome type I. Acta Otolaryngol 2013;133:345-51.